1. Home
  2. Staff
  3. University Academic Staff
  4. Dr Li Xue, Shirley

Dr Li Xue, Shirley 李雪

Dr Shirley Li

Assistant Professor

  • BEng, MMed, PhD
email sxueli@hku.hk
email 2255 3319
email HKU Scholars Hub
Biography

Dr Li is jointly appointed by the Department of Medicine, School of Clinical Medicine, and the Department of Pharmacology and Pharmacy at HKU. Before joining HKU, she obtained Master of Medicine at Peking Union Medical College, Tsinghua University and a PhD in Public Health at the Chinese University of Hong Kong.

Dr Li’s primary research interests lie in health technology assessment (HTA), health economics and real-world outcome (HEOR) research using decision analytic models and routine health records. Dr Li has expertise in healthcare data analytics, cost-effectiveness modelling and health policy evaluation. Since joining HKU, Dr Li has led and contributed to many HEOR projects, all of which involves dynamic interactions with local and international academic collaorators, local government, industry partners, NGOs and other key opinion leaders.

Dr Li’s recent research focuses on 1) investigating the real-world utilization, safety and cost-effectiveness of biological medicine; 2) identifying the unmet needs and care burden using healthcare big data; 3) conducting Horizon Scanning of cutting therapies for major chronic diseases in the global R&D pipeline and 4) the development of outcome-based risk-sharing model for high-cost drug enlisting. As a core member of CARE Programme (COVID-19 Vaccines Adverse Events Response and Evaluation Programme, https://www.hkcare.hku.hk/ ), Dr Li has led and contributed to several territory-wide, population-based vaccine safety assessement, particulary for people with immunological conditions. Dr Li also acts as a co-investigator of AI and Pharmaceuticals in Non-Communicable Diseases (Program 4) at the Laboratory of Data Discovery for Health (D²4H, https://www.d24h.hk ).

Dr Li’s research work has been supported by RGC/Research Impact Fund (Project Coordinator), RGC/Early Career Scheme (PI), RGC Collaborative Research Fund (co-PI), Health and Medical Research Fund of the Food and Health Bureau of Hong Kong SAR Government (PI and co-I) and the National Natural Science Foundation of China (co-I). She also maintained long-term collaboration with regional and global pharmaceutical companies. Dr Li has published actively in the field of pharmacoepidemiology, health service and health policy research. She has co-authored more than 100 research articles including top-tier specialty journals in Lancet, JAMA, BMJ and Nature families.

Research Profile

Research Interests

  • Health techonology assessment
  • Rountine care data and real-world outcome research
  • Decision modelling for chronic disease management
  • Health service and policy research

 

Diagrams

Figure 1 ‘Caring for Mental Health’ The Cover Issue of May 2022, Lancet Regional Health Western Pacific (Publication Highlight 2)
Figure 2 ‘Fighting for Health Equity’ The Cover Issue of September 2022, Lancet Regional Health Western Pacific (Publication Hight 3)

 

Publications
Publication Highlights
  1. Chan AYL, Chan VKY, Olsson S, Fan M, Jit M, Gong M, Zhang S, Ge M, Pathadka S, Chung CCY, Chung BHY, Chui CSL, Chan EW, Wong GHY, Lum TY, Wong ICK, Ip P*, Li X*. Access and unmet needs of orphan drugs in 194 Countries and six areas: a global policy review with content analysis. Value in Health. 2020 Dec; 23(12):1580-159 (IF 5.728, 4/88 in Health Policy & Services, Q1; selected equity access tools for Rare Disease International, https://www.rarediseasesinternational.org/equity-access-tools/).
  2. Chan VKY, Cheung ECL, Chan Sandra SM, Knapp M, Hayes JF, Min F, Lai FTT, Luo H, Lum T, Wong RSM, Lau LKW, Wan EYF, Wong GHY, Chan EW, Ip P, Wong ICK*, Li X*. Mortality-causing mechanisms and healthcare resource utilisation of treatment-resistant depression: a six-year population-based cohort study. The Lancet Regional Health Western Pacific, Volume 22, 100426, May 01, 2022. (IF 8.599, 3/109 in Health Care science & Service, Q1; Cover Issue of May 2022 with media-release https://www.med.hku.hk/en/news/press/20220317-treatment-resistant-depression ).
  3. Tong XN, Li X*, Pratt NL, Hillen JB, Stanford T, Ward M, Roughead EE, Lai ECC, Shin JY, Cheng FWT, Peng K, Lau CS, Leung WK, Wong ICK. Monoclonal antibodies and Fc-fusion protein biologic medicines:  a multinational cross-sectional investigation of accessibility and affordability in Asia Pacific regions between 2010 and 2020. Lancet Regional Health Western Pacific, Volume 26, 100506, September 01, 2022. (IF 8.599, 3/109 in Health Care science & Service, Q1; Cover Issue of September 2022).
  4. Li X, Tong X, Yeung WWY, Peng K, Yum SHH, Chui CSL, Lai FTT, Wan EYF, Wong CKH, Chan EW, Lau CS, Wong ICK. Two-dose Covid-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong. Annals of the Rheumatic Diseases. 2022 Apr;81(4):564-568 (IF 27.973, 3/34 in Rheumatology, Q1; 2022 Research Output Prize, LKS Faculty of Medicine, University of Hong Kong).

 

Selected Publications Selected publication as first, co-first, and corresponding authors 
[*Corresponding author, # Co-first author]

  1. Li X, Peng K, Cheng FWT, Lam DCL, Cheung CL, Chui CSL, Lai FTT, Wan EYF, Wong CKH, Ma T, Yum SHH, Chan EWY, Huang JD, Lau CS, Ip MSM, Wong ICK. Tuberculosis following two-dose SARS-CoV-2 vaccination with messenger RNA vaccine (BNT162b2) and inactivated virus vaccine (CoronaVac). Journal of Infection. 2022 Dec 17:S0163-4453(22)00706-X. doi: 10.1016/j.jinf.2022.12.016. (IF 38.637, Rank 4/95 in Infectious Diseases, Q1).
  2. Li X, Tong X, Yeung WWY, Peng K, Yum SHH, Chui CSL, Lai FTT, Wan EYF, Wong CKH, Chan EW, Lau CS, Wong ICK. Two-dose Covid-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong. Annals of the Rheumatic Diseases. 2022 Apr;81(4):564-568. (IF 27.973, 3/34 in Rheumatology, Q1).
  3. Li X, Tong X, Wong ICK, Peng K, Chui CSL, Lai FTT, Wan EYF, Wong CKH, Leung WK, Chan EW. Lack of inflammatory bowel disease flare-up following two-dose BNT162b2 vaccine: a population-based cohort study. Gut Published Online First: 08 February 2022. doi: 10.1136/gutjnl-2021-326860 (IF 31.840, 4/93 in Gastroenterology & Hepatology, Q1).
  4. Li X, Lai FTT, Chua GT, Kwan MYW, Lau YL, Ip P, Wong ICK. Myocarditis following the single-dose recommendation of BNT162b2 among adolescents in Hong Kong. JAMA Pediatrics. Published online February 25, 2022. doi:10.1001/jamapediatrics.2022.0101 (IF 26.821, 2/130 in Pediatrics, Q1).
  5. Lai FTT, Li X#, Peng K, Huang L, Ip P, Tong X, Chui CSL, Wan EYF, Wong CKH, Chan EW, Siu D, Wong ICK. Carditis after covid-19 vaccination with a messenger RNA vaccine and an inactivated virus vaccine: A Case-Control Study. Annals of Internal Medicine. 2022 Jan 25. 2022 Mar;175(3):362-370. (IF 51.598, 6/172 in Medicine, General & Internal, Q1).
  6. Li X, Gao L, Tong X, Chan VKY, Chui CSL, Lai FTT, Wong CKH, Wan EYF, Chan EWY, Lau KK, Lau CS, Wong ICK. Autoimmune conditions following mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccination: a descriptive cohort study among 1.1 million vaccinated people in Hong Kong. Journal of Autoimmunity. 2022 Apr 14;130:102830 (IF 14.511, 16/161 in Immunology, Q1).
  7. Yu QY, Li X#,*, Fan M, Qiu H, Wong AYS, Tian LW, Chui CSL, Li PH, Lau LKW, Chan EW, Goggins WB, Ip P, Lum TY, Hung IFN, Cowling BJ, Wong ICK, Jit M. The impact of childhood pneumococcal conjugate vaccine immunization on all-cause pneumonia admissions in Hong Kong: a 14-year population-based interrupted time series analysis. Vaccine. 2021 May 6;39(19):2628-2635 (IF 4.169, 94/161 in Immunology, Q3).
  8. Li X, Pathadka S, Man KK, Ng VW, Siu CW, Wong ICK, Chan EW, Lau WCY. Comparative outcomes between direct oral anticoagulants, warfarin, and antiplatelet monotherapy among Chinese patients with atrial fibrillation: A Population-Based Cohort Study. Drug Safety.2020 Oct;43(10):1023-1033 (IF 5.228, 67/279 in Pharmacology and Pharmacy, Q1).
  9. Chan VKY, Yang RQ, Wong ICK, Li X*. Cost-effectiveness of poly ADP-ribose polymerase inhibitors in cancer treatment: a systematic review. Frontiers in Pharmacology. 2022 (in-press). (IF 5.988, 50/279 in Pharmacology and Pharmacy, Q1).
  10. Tong XN, Li X*, Pratt NL, Hillen JB, Stanford T, Ward M, Roughead EE, Lai ECC, Shin JY, Cheng FWT, Peng K, Lau CS, Leung WK, Wong ICK. Monoclonal antibodies and Fc-fusion protein biologic medicines:  a multinational cross-sectional investigation of accessibility and affordability in Asia Pacific regions between 2010 and 2020. Lancet Regional Health Western Pacific. 2022 Jun 24;26:100506. (IF 8.599, 3/109 Health Care Science & Service, Q1).   
  11. Chan VKY, Cheung ECL, Chan Sandra SM, Knapp M, Hayes JF, Min F, Lai FTT, Luo H, Lum T, Wong RSM, Lau LKW, Wan EYF, Wong GHY, Chan EW, Ip P, Wong ICK*, Li X*. Mortality-causing mechanisms and healthcare resource utilisation of treatment-resistant depression: a six-year population-based cohort study. Lancet Regional Health Western Pacific. 2022 Mar 15;22:100426. (IF 8.599, 3/109 Health Care Science & Service, Q1).
  12. Zhang Y, Li X*, Chan VKY, Luo H, Chan SSM, Wong GHY, Wong ICK, Lum TYS. Depression duration and risk of incident cardiovascular disease: A population-based six-year cohort study. Journal of Affective Disorder. 2022 Mar 15;305:188-195. (IF 6.533, 37/155 in Psychiatry, Q1).
  13. Fan M, Chan AY, Yan VKC, Tong X, Lau LKW, Wan EYF, Tam EYY, Ip P, Lum TY, Wong ICK, Li X*. Postmarketing safety of orphan drugs: a longitudinal analysis of the US Food and Drug Administration database between 1999 and 2018. Orphanet Journal of Rare Diseases. 2022 Jan 4;17(1):3. doi: 10.1186/s13023-021-02166-9. (IF 4.307, 61/175 in Genetics & Heredity, Q2).
  14. Chan AY, Chan VK, Olsson S, Fan M, Jit M, Gong MC, Zhang SY, Ge MQ, Pathadka S, Chui CSL, Chan EW, Chung CCY, Chung BHY, Wong GHY, Lum TY, Wong ICK, Ip P*, Li X*. Access and unmet needs of orphan drugs in 194 Countries and six areas: a global policy review with content analysis. Value in Health. 2020 Dec;23(12):1580-1591 (IF 5.101, 9/88 in Health Policy & Services, Q1). 
  15. Shami JP, Patha S, Chan EW, Hui J, Sato R, Patil S, Li X*. Evaluating the cost-effectiveness of a sequential pneumococcal vaccination compared to single dose vaccination strategy for adults in Hong Kong. Human Vaccines & Immunotherapeutics. 2020 Aug 2;16(8):1937-1944. (IF 4526, 86/161 in Immunology, Q3).
  16. Ge MQ, Man KK, Chui CS, Chan EW, Wong ICK, Li X*. Prevalence, safety and long-term retention rates of biologics in Hong Kong from 2001-2015. Drug Safety. 2019 Sep;42(9):1091-1102. (IF 5.228, 67/279 in Pharmacology and Pharmacy, Q1).

    Total number of refereed papers = 129; h-index: 23; Full publication list available at:
    ResearchGate https://www.researchgate.net/profile/Xue-Li-23 
    Google Scholar:  https://scholar.google.com/citations?user=FkHhrtMAAAAJ&hl=en  

Memberships
  • 2022-Present Scientific and Medical Advisory Committee of Rare Disease Hong Kong
  • 2022-Present Scientific Advisor for Rare Disease International (RDi)
  • 2021-Present Member of The Observational Health Data Sciences and Informatics (OHDSI) APAC Steering Committee
  • 2019-Present Degree Board Member Master of Medical Science, Master of Clinical Pharmacy at LKS Faculty of Medicine, University of Hong Kong
  • 2019-Present Member of international Health Technology Assessment (iHTA)
  • 2014-Present Member of International Society for Pharmacoeconomics and Outcomes Research (ISPOR), ISPOR Asia Consortium
 

Funding

External competitive grants in PC, PI and co-PI capacity

2023-26 Horizon Scanning of medium- to long-term burden of Chronic diseases And care Needs to 2030 in Hong Kong (SCAN-2030). Research Grant Council, Research Impact Fund (Ref: r7007-22F), Project Coordinator (HK$4,214,286), ongoing

2021-23 Cost-effectiveness of biologic originators versus biosimilars in patients with established rheumatoid arthritis: an application of real-world big data and disease simulation modeling. Research Grant Council, Early Career Scheme (Ref: 27603421), Principal Investigator (HK$697,970), ongoing

2021-24 A multinational big data Covid-19 Epidemiological Study on post-infection Outcomes (ACESO) Collabortive Research Fund, Research Grants Council (RGC Collaborative Research Fund (CRF) Coronavirus Disease (COVID-19) and Novel Infectious Disease (NID) Research Exercise Ref: C7154-20G),  co-Principal Investigator (HK$9,691,060), ongoing

2019-20 The impact of childhood pneumococcal conjugate vaccine (PCV) immunisation on pneumonia admissions in Hong Kong: a population-based interrupted time series analysis from 2004-2017, Health and Medical Research Fund (HMRF), Food and Health Bureau of the Government of Hong Kong, Principal Investigator (HK$ 551,706), completed

 

Collaborative/contract research in PI capacity

2020-23 Understanding the barriers of using novel disease-modifying antirheumatic drugs among patients with autoimmune diseases in Hong Kong, Pfizer, Principal Investigator (HK$600,000 and UGC-Research Matching Fund: HK$ 99,633.75), ongoing

2020-22 Cost-effectiveness of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation in Hong Kong, Pfizer, Principal Investigator (HK$558,969 and UGC-Research Matching Fund: HK$93,104.75), completed

2020-23 Economic Model of Burden of Major Depression, Jansson, Principal Investigator (HK$693,840 and UGC-Research Matching Fund: HK$230,432.7), coompleted

Total Grant monies awarded = ~HK$8,761,267 (as PC/PI); $20,714,816 (as co-I)


Other Information

Current team members

Dr Deliang YANG (Postdoctoral Fellow)
Dr Mallory Man Yee LEUNG (Research Associate)
Ms Yin ZHANG (Research Assistant)
Ms Jingqi ZHANG (primary-supervisor, PhD candidate, 2023-)
Mr Kuan PENG (primary-supervisor, PhD candidate, 2022-)
Ms Qiuyan YU (co-supervisor, PhD candidate, 2021-)
Ms Vivien Kin Yi CHAN (co-supervisor, PhD candidate, 2020-)
Mr Yingyang ZHANG (co-supervisor, PhD candidate, 2019-)
Ms Ziyan XIAO (Student Research Assistant)
Dr Xinning TONG (Honorary Research Associate)

Collaborative institutions (by alphabetic order)

Chinese University of Hong Kong, Hong Kong SAR
Fudan University, China
Hong Kong Association of the Pharmaceutical Industry, Hong Kong SAR
London School of Economics and Political Science, UK
National Cheng Kung University, Taiwan
Newcastle University, UK
Queen Mary Hospital
Rare Disease Hong Kong, Hong Kong SAR
Rare Disease international (RDi)
Sungkyunkwan University, South Korea
Tianjin University, China
UCL School of Pharmacy, UK
University of South Australia, Australia

Seeking PhD candidates, Research Assistants and Postdoctoral Fellows

I am seeking highly organised and motivated postdoctoral fellows and PhD candidates in area of Health Technology Assessment, Pharmacoepidemiology and Pharmacoeconomics. Team members will work on EHR based unmet need identification, medication safety assessment, cost-benefit/cost-effective evaluation of biologics and the innovative solutions to improve the ealy treatment accessibility and affordability of biological medicine, vaccine and orphan drugs. Interested candidates please email Dr Li (sxueli@hku.hk) with your CV, transcripts, and publications (if any) for our consideration.

Office PB306, Queen Mary Hospital, 102 Pok Fu Lam Road, Hong Kong

ORCID: orcid.org/0000-0003-4836-7808